Pharming Group’s (PHAR) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Pharming Group (NASDAQ:PHAR) in a research note issued to investors on Wednesday morning,Benzinga reports. The firm currently has a $37.00 target price on the stock.

A number of other analysts also recently weighed in on PHAR. Oppenheimer cut their target price on Pharming Group from $31.00 to $30.00 and set an “outperform” rating for the company in a research report on Monday, October 28th. Jefferies Financial Group initiated coverage on shares of Pharming Group in a research report on Monday. They set a “buy” rating and a $14.00 price objective for the company.

Pharming Group Stock Up 6.1 %

NASDAQ PHAR opened at $9.27 on Wednesday. The company has a current ratio of 3.53, a quick ratio of 2.76 and a debt-to-equity ratio of 0.41. The company has a market cap of $628.83 million, a price-to-earnings ratio of -35.65 and a beta of 0.05. The company has a 50 day moving average of $8.23 and a 200-day moving average of $8.14. Pharming Group has a 1-year low of $6.65 and a 1-year high of $13.20.

Institutional Investors Weigh In On Pharming Group

A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC lifted its holdings in shares of Pharming Group (NASDAQ:PHAR) by 75.4% in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 41,110 shares of the company’s stock after buying an additional 17,675 shares during the period. Silverberg Bernstein Capital Management LLC owned about 0.06% of Pharming Group worth $339,000 as of its most recent filing with the SEC. Institutional investors own 0.03% of the company’s stock.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.